Denali Capital Acquisition CORP 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Semnur Pharmaceuticals has signed a binding term sheet for a $100 million strategic investment from iHolding Group LLP to advance its pipeline, including the SEMDEXA Phase 3 program.
Semnur Pharmaceuticals, Inc. successfully concluded its 2026 Annual Meeting of Stockholders, confirming the election of a director and the approval of key equity incentive plans.
Semnur Pharmaceuticals, Inc. announced the termination of two significant securities purchase agreements, one with JW Capital Securities Limited and another with Biconomy PTE. Ltd.
Semnur Pharmaceuticals, Inc. announced the retirement of its CEO and President, Jaisim Shah, and the appointment of Henry Ji, Ph.D., as the new CEO and President, and Stephen Ma as Chief Operating Officer.
Semnur Pharmaceuticals, Inc. filed an 8-K to update its securities description and corporate governance following its September 2025 business combination.
Semnur Pharmaceuticals, Inc. finalized its business combination, becoming a public entity and announcing a significant $100 million equity investment paid in Bitcoin.
Denali Capital Acquisition Corp. shareholders overwhelmingly approved the business combination with Semnur Pharmaceuticals, Inc., including domestication to Delaware and related governance changes.
Denali Capital Acquisition Corp. announced a $20 million private investment in public equity (PIPE) financing to support its merger with Semnur Pharmaceuticals, Inc.
Denali Capital Acquisition Corp. deposited $874.78 into its Trust Account to extend the deadline for consummating a business combination by one month to September 11, 2025.
Denali Capital Acquisition Corp. has amended its merger agreement with Semnur Pharmaceuticals, Inc. to allow for the issuance of additional shares for potential private placement financing and advisor compensation, while maintaining the original exchange ratio.
Denali Capital Acquisition Corp. has extended its deadline to complete a business combination by one month to August 11, 2025, by depositing $874.78 into its Trust Account.
Denali Capital Acquisition Corp. has extended its deadline to complete a business combination by one month to July 11, 2025, funded by a convertible promissory note from Scilex Holding Company.
Denali Capital Acquisition Corp. extends its business combination deadline to June 11, 2025, by depositing $874.78 into its trust account.
Denali Capital Acquisition Corp. and Semnur Pharmaceuticals have amended their merger agreement to address Denali's delisting from Nasdaq and subsequent quotation on the OTC Markets, among other changes.
Denali Capital Acquisition Corp. secures shareholder approval to extend its business combination deadline to December 11, 2025, and funds the initial one-month extension.
8-K: Denali Capital Acquisition Corp. Faces Nasdaq Delisting Due to Non-Compliance with Listing Rules
Denali Capital Acquisition Corp. receives notice of delisting from Nasdaq due to failure to meet minimum Market Value of Listed Securities, Total Assets, and Public Float requirements.
Denali Capital Acquisition Corp. extends its business combination deadline to April 11, 2025, by depositing $15,063.74 into its trust account.
Denali Capital Acquisition Corp. extends its business combination deadline to March 11, 2025, by depositing $15,063.74 into its trust account.
Denali Capital Acquisition Corp. has extended its deadline to complete a business combination by one month, to February 11, 2025, by depositing $15,063.74 into its trust account.
Denali Capital Acquisition Corp. has extended its deadline to complete a business combination by one month, until January 11, 2025, by depositing $15,063.74 into its trust account.
Denali Capital Acquisition Corp. has extended its deadline to complete a business combination by one month, to December 11, 2024, by depositing $15,063.74 into its trust account.
Denali Capital Acquisition Corp. has extended its deadline to complete a business combination by one month, to November 11, 2024, by depositing $15,063.74 into its trust account.
Denali Capital Acquisition Corp. has received a notice from Nasdaq for failing to meet minimum market value and total asset requirements, placing its listing status at risk.
Denali Capital Acquisition Corp. has extended its deadline to complete a business combination by one month, to October 11, 2024, by depositing $15,063.74 into its trust account.
Semnur Pharmaceuticals, a subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. have signed a merger agreement for a business combination valuing Semnur at $2.5 billion.
Denali Capital Acquisition Corp. has extended its deadline to complete a business combination by one month through a convertible promissory note with Scilex Holding Company.
Denali Capital Acquisition Corp. has dismissed Marcum LLP as its independent auditor and appointed Marcum Asia CPAs LLP, effective July 15, 2024.
Denali Capital Acquisition Corp. has successfully extended its deadline to complete a business combination to April 11, 2025, through shareholder approval and a convertible promissory note.
Semnur Pharmaceuticals and Denali Capital Acquisition Corp. have signed a letter of intent for a business combination, valuing Semnur at up to $2.0 billion.
Denali Capital Acquisition Corp. and Longevity Biomedical, Inc. have mutually agreed to terminate their previously announced business combination agreement.